Follow us on Twitter
This page is updated frequently with new Autoimmune-related patent applications. Subscribe to the Autoimmune RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune RSS
|| List of recent Autoimmune-related patents
|Optical sensor device and image processing unit for measuring chemical concentrations, chemical saturations and biophysical parameters|
Optical sensor devices, image processing devices, methods and computer readable code computer-readable storage media for detecting biophysical parameters, chemical concentrations, chemical saturations, vital signs and physiological information such as a malignant condition are provided. In some embodiments, the optical sensor includes an array of photodetectors, where each photodetector is configured to detect a spectrum of light.
|Inhibitors of bruton's tyrosine kinase|
Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
|Crystalline forms of a bruton's tyrosine kinase inhibitor|
Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
|Amine derivatives as potassium channel blockers|
The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of kv1.3 channels found in t cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation..
|Silicon-containing fumaric acid esters|
The present invention is directed to silicon-containing fumaric acid esters of the formulae i-iv. The silicon-containing fumaric acid esters of formulae i-iv are useful in transplantation medicine and for the treatment of autoimmune diseases and autoimmune-related diseases.
|Methods for treating inflammation, autoimmune disorders and pain|
Disclosed herein are methods of treating, reducing, or preventing a disease such as oral mucositis, gastric mucositis, or inflammatory fibrosis, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (csa), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein..
|Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity|
A novel form of rugged dsrna with a unique composition and physical characteristics was identified with high specificity of binding to tlr3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral ampligen® (poly i, poly c12,u) the new and improved form (poly i, poly c30,u) has a reduced tendency to form branched dsrna which results in increased bioactivity due to an increased ability to bind tlr3 receptor.
|Utility of insulin-like 6 (insl6) for the treatment of autoimmune diseases|
The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (insl6) agent, such as an insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of insl6 agents to reduce t-regulatory (treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease.
|Method of isolating human antibodies|
Provided is a novel method of isolating and producing human antibodies with desired specificity from human b cells. In particular, a method of isolating human antibodies from memory b cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described..
A new fusion protein which can specifically suppress the autoantibodies, which can effectively prevent or treat the autoimmune disease of autoantibody type, and which can be expressed in an amount sufficient for industrial production. A fusion protein, characterized in that, a protein (x) containing a site recognized by autoantibodies which are a cause of the autoimmune disease of autoantibody type is connected to a protein (a) containing a fragment of the antibody heavy chain constant region which exhibits the antibody-dependent cellular cytotoxicity with a linker peptide (l) consisting of one or more amino acid(s), wherein the protein (x), the linker peptide (l) and the protein (a) are connected in this order by means of peptide bond from n terminal to c terminal..
|Immunoglobulin constant region fc receptor binding agents|
Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function.
|Small molecule inhibitors of stat3 with anti-tumor activity|
The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s31-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
|Inhibitors of c-fms kinase|
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
|Heterocyclic protein kinase inhibitors|
The present invention provides protein kinase having one of the following structures (i), (ii) or (iii): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein r, r1, r2 and x are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other pim kinase-associated conditions are also disclosed..
|Methods of treating a subject and related particles, polymers and compositions|
Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders.
|Her2/neu-specific antibodies and methods of using same|
This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
|Mesenchymal stem cells and uses therefor|
Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
|Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors|
Wherein x1 to x5, y, za, zb, r and a have the meaning as cited in the description and the claims. Said compounds are useful as kinase inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases.
|Imidazopyridine derivatives as pi3 kinase|
This invention relates to the use of imidizopyridine derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of imidizopyridines in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
|Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents|
The present document describes compounds of formula i, pharmaceutical compositions comprising the same as well as methods of treating diseases such as a cancer, neurological disease, neurodegenerative disorder, stroke, traumatic brain injury, parasitic infection, inflammation or an autoimmune disease with said compounds.. .
|Peptides for treatment of bone deficiency and autoimmune disorders|
The present invention concerns the use of hyd1 peptides to reduce activated t-cell numbers and/or to promote bone preservation in vivo. The present invention concerns methods of treating a bone deficiency and/or an autoimmune disorder, comprising administering an effective amount of a hyd1 peptide.
|Tolerizing treatments for autoimmune disease|
The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory t-cells from the patient or a compatible donor, or (iii) a combination of regulatory t-cells and a compound identified by the methods described herein.
|Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis|
A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder by measuring the value of a biomarker selected from the group consisting of il-10 concentration, il-17 concentration, il-18 concentration, tnf-α concentration, bdnf concentration, caspase-1 concentration, il-10/il-18 ratio and il-10/il-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramer acetate hypo-/non-responder.. .
|Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities|
Which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-fms (csf-1r), c-kit, and/or pdgfr kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-fms, c-kit, or pdgfr kinases..
|3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h- pyrrolo[2,3-b]pyrazine dual itk and jak3 kinase inhibitors|
Salts thereof, their synthesis, and their use as itk and jak3 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such disease associated with abnormal cell growth such as autoimmune, inflammation, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, ulcerative colitis, psoriatic arthritis, psoriasis, crohn's, metabolic and cancer diseases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions and processes for preparing the compounds of the invention..
|Novel heterocyclic derivatives and their uses|
The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type i) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer..
|Therapeutically active thiazolo-pyrimidine derivatives|
A series of thiazolo[5,4-d]pyrimidine derivatives of formula (i) or an n-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (i) q represents a group of formula (qa), (qb), (qc), (qd) or (qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.. .
|Materials and methods for modulating immune responses|
The present invention provides nanoparticle-coupled tolerogenic treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (sle), multiple sclerosis (ms), inflammatory bowel disease (ibd), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with graft versus host disease (gvhd) following hematopoietic stem cell transplantation..
|Bi-specific antibodies for medical use|
A bispecific antibody format devoid of an active fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on b-cells, for use in the treatment or prevention of b cell mediated autoimmune diseases.. .
|Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment|
A novel approach to discover new drugs against ms and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (il-12), the p40 monomer (p40), the p40 homodimer (p402), and the il-23.
Popular terms: [SEARCH]
Autoimmune topics: Autoimmune, Immune Disease, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Transplant, Immune Disorder, Autoimmune Disorder, Autoimmune Disorders, Infectious, Infectious Disease, Inflammatory Disease, Type 1 Diabetes, Proliferative Disorder, Recurrence
Follow us on Twitter
This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.